{"component": "definition", "props": {"groups": [{"samples": [{"hash": "aiienjUsC7i", "uri": "/contracts/aiienjUsC7i#active-compound", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 30.1772758385, "published": true}, {"hash": "ib2kw5Wacez", "uri": "/contracts/ib2kw5Wacez#active-compound", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 25.1752224504, "published": true}, {"hash": "2022DYIeiMZ", "uri": "/contracts/2022DYIeiMZ#active-compound", "label": "Collaboration Agreement (Sunesis Pharmaceuticals Inc)", "score": 22.492128679, "published": true}], "snippet_links": [{"key": "chemical-compound", "type": "definition", "offset": [16, 33]}, {"key": "collaboration-target", "type": "definition", "offset": [70, 90]}, {"key": "each-case", "type": "definition", "offset": [150, 159]}], "snippet": "means a soluble chemical compound that can bind non-covalently to the Collaboration Target or a Target for which such compound is counterscreened, in each case where such compound { * }.", "size": 7, "hash": "d8295f26055c941a67779b2ee6c45448", "id": 1}, {"samples": [{"hash": "gtkXHUyyiQD", "uri": "/contracts/gtkXHUyyiQD#active-compound", "label": "Sublicense Agreement (Ligand Pharmaceuticals Inc)", "score": 33.1587953457, "published": true}, {"hash": "2QGbemhZV9e", "uri": "/contracts/2QGbemhZV9e#active-compound", "label": "Sublicense Agreement (Ligand Pharmaceuticals Inc)", "score": 31.1546885695, "published": true}, {"hash": "4mSWBEqzcT9", "uri": "/contracts/4mSWBEqzcT9#active-compound", "label": "Sublicense Agreement (Desert Gateway, Inc.)", "score": 23.9650924025, "published": true}], "snippet_links": [{"key": "appendix-2", "type": "definition", "offset": [29, 39]}], "snippet": "has the meaning set forth in Appendix 2 hereto.", "size": 5, "hash": "82e5775a4bb3cef9af5bc3a593abfe7b", "id": 2}, {"samples": [{"hash": "b7BQBB7benp", "uri": "/contracts/b7BQBB7benp#active-compound", "label": "Manufacturing Services Agreement", "score": 31.340862423, "published": true}, {"hash": "bAdI2iILPlW", "uri": "/contracts/bAdI2iILPlW#active-compound", "label": "Manufacturing Services Agreement (Reliant Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "aViUS0pnmBW", "uri": "/contracts/aViUS0pnmBW#active-compound", "label": "Manufacturing Services Agreement (Reliant Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet_links": [], "snippet": "or \u201cAPI\u201d means Isradipine;", "size": 5, "hash": "e04893589aac437894a48c28bcc996c3", "id": 3}, {"samples": [{"hash": "ivbFIPA2PWy", "uri": "/contracts/ivbFIPA2PWy#active-compound", "label": "Collaborative Research, Development and License Agreement (Acadia Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "g68octATLTs", "uri": "/contracts/g68octATLTs#active-compound", "label": "Collaborative Research, Development and License Agreement (Acadia Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "aqfElxNyU2y", "uri": "/contracts/aqfElxNyU2y#active-compound", "label": "Collaborative Research, Development and License Agreement (Acadia Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "small-molecule", "type": "definition", "offset": [8, 22]}, {"key": "the-production", "type": "clause", "offset": [82, 96]}], "snippet": "means a small molecule that specifically inhibits, stimulates or otherwise alters the production or activity of a Target.", "size": 4, "hash": "11f3e34dd5e9dd01d251a3508bc01bd8", "id": 4}, {"samples": [{"hash": "2O92DJvHcqh", "uri": "/contracts/2O92DJvHcqh#active-compound", "label": "Compound Library and Option Agreement (Unity Biotechnology, Inc.)", "score": 32.2224503765, "published": true}, {"hash": "ilcKFaJepkr", "uri": "/contracts/ilcKFaJepkr#active-compound", "label": "Compound Library and Option Agreement (Unity Biotechnology, Inc.)", "score": 29.3066392882, "published": true}, {"hash": "4AYbiA6uEZx", "uri": "/contracts/4AYbiA6uEZx#active-compound", "label": "Compound Library and Option Agreement (Unity Biotechnology, Inc.)", "score": 29.257357974, "published": true}], "snippet_links": [], "snippet": "means an Ascentage Active Compound or a Unity Active Compound, as applicable.", "size": 4, "hash": "bad24bb17c389449f8e33d7a3388c815", "id": 5}, {"samples": [{"hash": "yxQEz1Xf7P", "uri": "/contracts/yxQEz1Xf7P#active-compound", "label": "Collaborative Research and License Agreement (Targacept Inc)", "score": 21.0, "published": true}, {"hash": "dhwpoHoGgwj", "uri": "/contracts/dhwpoHoGgwj#active-compound", "label": "Collaborative Research and License Agreement (Targacept Inc)", "score": 21.0, "published": true}, {"hash": "d1LHv8ZOHGU", "uri": "/contracts/d1LHv8ZOHGU#active-compound", "label": "Collaborative Research and License Agreement (Targacept Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "collaboration-candidate", "type": "definition", "offset": [11, 34]}, {"key": "terminated-compound", "type": "definition", "offset": [49, 68]}, {"key": "the-jrc", "type": "clause", "offset": [91, 98]}, {"key": "during-the-research-program-term", "type": "clause", "offset": [114, 146]}, {"key": "tail-period", "type": "definition", "offset": [154, 165]}, {"key": "such-determination", "type": "definition", "offset": [241, 259]}, {"key": "pursuant-to-section", "type": "clause", "offset": [260, 279]}, {"key": "finally-determined", "type": "definition", "offset": [326, 344]}, {"key": "in-accordance-with", "type": "definition", "offset": [357, 375]}, {"key": "if-applicable", "type": "clause", "offset": [403, 416]}, {"key": "section-143", "type": "clause", "offset": [448, 460]}, {"key": "for-purposes-of", "type": "clause", "offset": [595, 610]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [677, 706]}, {"key": "the-parties", "type": "clause", "offset": [715, 726]}, {"key": "in-writing", "type": "definition", "offset": [743, 753]}, {"key": "execution-date", "type": "clause", "offset": [798, 812]}], "snippet": "means each Collaboration Candidate that is not a Terminated Compound that is determined by the JRC or AstraZeneca during the Research Program Term or the Tail Period to satisfy the Active+ Criteria (unless and until (a) Targacept challenges such determination pursuant to Section 4.3.2 and (b) such Collaboration Candidate is finally determined by the ESC (in accordance with Section 2.1.5(c)(iii)) or, if applicable, an Expert (in accordance with Section 14.3) to not satisfy the Active+ Criteria), including any salt form, polymorph, crystalline form, hydrate, solvate or formulation thereof. For purposes of clarity, all Active+ Compounds are also Collaboration Candidates. Notwithstanding the foregoing, unless the Parties otherwise agree in writing, the Compounds known to Targacept as of the Execution Date as [********] and, [********], including any salt form, polymorph, crystalline form, Prodrug, metabolite (other than any such metabolite that is an Excluded Zone Compound), hydrate, solvate or formulation thereof, shall not be Active+ Compounds.", "size": 4, "hash": "eb6057c64b277095f6c7744fae7f6e7e", "id": 6}, {"samples": [{"hash": "hY4GwfTQfsU", "uri": "/contracts/hY4GwfTQfsU#active-compound", "label": "Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "e9ylXQju5Nm", "uri": "/contracts/e9ylXQju5Nm#active-compound", "label": "Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "pursuant-to-the", "type": "clause", "offset": [86, 101]}, {"key": "screening-program", "type": "definition", "offset": [102, 119]}, {"key": "the-applicable", "type": "clause", "offset": [221, 235]}, {"key": "the-steering-committee", "type": "definition", "offset": [260, 282]}, {"key": "the-procedure", "type": "clause", "offset": [319, 332]}, {"key": "paragraph-3", "type": "clause", "offset": [346, 357]}], "snippet": "means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which (a) has Kd values of [*] and (b) has demonstrated bioactivity in functional assays against the applicable Target as determined by the Steering Committee following Schering's performance of the procedure specified in Paragraph 3 of ATTACHMENT A.", "size": 4, "hash": "8c1cd9e57bd138e2bbedb2497da25a76", "id": 7}, {"samples": [{"hash": "6ZUigLf0hx5", "uri": "/contracts/6ZUigLf0hx5#active-compound", "label": "Research Collaboration and Licensing Agreement (Samaritan Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "1TX6ipV1AG4", "uri": "/contracts/1TX6ipV1AG4#active-compound", "label": "Research Collaboration and Licensing Agreement (Samaritan Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "active-materials", "type": "definition", "offset": [28, 44]}, {"key": "arise-from", "type": "definition", "offset": [50, 60]}, {"key": "patent-rights", "type": "definition", "offset": [75, 88]}, {"key": "licensed-technology", "type": "definition", "offset": [173, 192]}], "snippet": "means such pharmaceutically active materials that arise from or out of the Patent Rights and/or such other pharmaceutically active materials as may arise from or out of the Licensed Technology.", "size": 4, "hash": "9934db3e6d9f0926bf6fb186e3dcf7e2", "id": 8}, {"samples": [{"hash": "eCixIEupmO3", "uri": "/contracts/eCixIEupmO3#active-compound", "label": "Collaborative Discovery and Lead Optimization Agreement (3 Dimensional Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "4Fvo2auaLw9", "uri": "/contracts/4Fvo2auaLw9#active-compound", "label": "Collaborative Discovery and Lead Optimization Agreement (3 Dimensional Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "34sgrJth7BR", "uri": "/contracts/34sgrJth7BR#active-compound", "label": "Collaborative Discovery and Lead Optimization Agreement (3 Dimensional Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "derivative-compound", "type": "definition", "offset": [24, 43]}, {"key": "clinical-development", "type": "clause", "offset": [106, 126]}], "snippet": "means a 3DP Compound or Derivative Compound that has been formally selected by DPC for preclinical and/or clinical development.", "size": 3, "hash": "62f443d48f5247a00b94272a0ab75c22", "id": 9}, {"samples": [{"hash": "gDaO9gmofbg", "uri": "/contracts/gDaO9gmofbg#active-compound", "label": "Array Delivery and Testing Agreement (Arqule Inc)", "score": 21.0, "published": true}, {"hash": "903uOL3h9Mk", "uri": "/contracts/903uOL3h9Mk#active-compound", "label": "Array Delivery and Testing Agreement (Arqule Inc)", "score": 18.0, "published": true}, {"hash": "14Bd3fXhRRe", "uri": "/contracts/14Bd3fXhRRe#active-compound", "label": "Array Delivery and Testing Agreement (Arqule Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "active-arqule-compound", "type": "definition", "offset": [10, 32]}], "snippet": "means any Active ArQule Compound or Active Monsanto Compound.", "size": 3, "hash": "bb6aa33db2f22cec062465871398bb28", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYYWN0aXZlLWNvbXBvdW5kIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means a soluble chemical compound that can bind non-covalently to the Collaboration Target or a Target for which such compound is counterscreened, in each case where such compound { * }.", "title": "Active Compound", "size": 138, "id": "active-compound", "examples": ["Furthermore, following the end of the Research Term, Infinity shall not modify by chemical and/or molecular-genetic means any Licensed Compound then on the <strong>Active Compound</strong> List, other than in accordance with this Agreement.", "In particular, during the initial two (2) year Research Term, Novartis shall dedicate at least [**] FTEs simultaneously to seek to identify a Research Program <strong>Active Compound</strong> as a development candidate for GLP toxicology testing leading to the filing of an IND with respect to a Licensed Product.", "Following the expiration of the Research Period, <strong>Active Compounds</strong> with respect to which ImClone fails to proceed with Due Diligence shall be deemed to be Inactive Compounds for all purposes hereunder; provided, that any <strong>Active Compound</strong> which is the subject of claim(s) under a pending Patent shall continue to be treated as an <strong>Active Compound</strong> during the Exclusivity Period so long as ImClone exercises Due Diligence with respect to any Collaboration Compound.", "Following the Research Term but during the Term, Novartis shall revise the <strong>Active Compound</strong> List to specify the Analogs designed, discovered or synthesized by or on behalf of Novartis after the Research Term and demonstrated during the Term to have Threshold Activity against a Target.", "Neither Party shall disclose the structure of any <strong>Active Compound</strong> to any Third Party without the other Party&#x27;s written permission, unless required to do so by law, in which case such Party shall promptly notify the other Party of such required disclosure.", "Under no circumstances whatsoever shall Patheon reimburse Client for the cost of the Granulations or the <strong>Active Compound</strong> contained within the Granulations (the \u201cPatheon Reimbursement\u201d) unless the loss of such Granulations occurred as a result of (i) Patheon\u2019s Negligence, as defined in subsection (f) below; or (ii) Patheon\u2019s gross negligence, intentional misconduct or fraud.", "Suitability of all compendia methodology will be demonstrated, and written in a report, prior to use for release of materials, <strong>Active Compound</strong>, components, or the Product(s).", "If ImClone elects not to file, maintain or prosecute such Patent, CombiChem shall have the right to take over such filing, maintenance or prosecution of such Patent, at its sole expense, and ImClone shall assign all intellectual property rights it may have in the <strong>Active Compound</strong>, Lead Compound, Development Compound or Product to CombiChem.", "At the time Unity designates a Development Candidate, Unity shall have the right to designate [***] <strong>Active Compound</strong> to be used to replace such Development Candidate in the event Unity elects to abandon development of such Development Candidate (each, a \u201cBack-up Compound\u201d), all as further specified in the applicable Compound License Agreements.", "Commencing on the date of Unity\u2019s receipt of any given New Compound Report and continuing for the duration of Term, Unity shall have the right to designate one or more Unity Compounds as Unity <strong>Active Compound</strong>, by providing Ascentage with written notice as described in Section 2.5.2(a) below and subject to the requirements of Section 2.5.2(b) below."], "related": [["lead-compound", "Lead Compound", "Lead Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"], ["product-candidate", "Product Candidate", "Product Candidate"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}